WWW.JNEUROSCI.ORG
-
The Journal of Neuroscience Join the Society for Neuroscience
 QUICK SEARCH:   [advanced]


     
-


HOME
  |  
SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (348)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moghaddam, B.
Right arrow Articles by Daly, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moghaddam, B.
Right arrow Articles by Daly, D.

 Previous Article

Volume 17, Number 8, Issue of April 15, 1997 pp. 2921-2927
Copyright ©1997 Society for Neuroscience

Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex

Received Sept. 23, 1996; revised Nov. 21, 1996; accepted Nov. 22, 1996.

Bita Moghaddam, Barbara Adams, Anita Verma, and Darron Daly

Department of Psychiatry, Yale University School of Medicine, VA Medical Center 116A/2, West Haven, Connecticut 06516

Subanesthetic doses of ketamine, a noncompetitive NMDA receptor antagonist, impair prefrontal cortex (PFC) function in the rat and produce symptoms in humans similar to those observed in schizophrenia and dissociative states, including impaired performance of frontal lobe-sensitive tests. Several lines of evidence suggest that ketamine may impair PFC function in part by interacting with dopamine neurotransmission in this region. This study sought to determine the mechanism by which ketamine may disrupt dopaminergic neurotransmission in, and cognitive functions associated with, the PFC. A thorough dose-response study using microdialysis in conscious rats indicated that low doses of ketamine (10, 20, and 30 mg/kg) increase glutamate outflow in the PFC, suggesting that at these doses ketamine may increase glutamatergic neurotransmission in the PFC at non-NMDA glutamate receptors. An anesthetic dose of ketamine (200 mg/kg) decreased, and an intermediate dose of 50 mg/kg did not affect, glutamate levels. Ketamine, at 30 mg/kg, also increased the release of dopamine in the PFC. This increase was blocked by intra-PFC application of the AMPA/kainate receptor antagonist, 6-cyano-7-nitroquinoxaline-2,3-dione CNQX. Furthermore, ketamine-induced activation of dopamine release and impairment of spatial delayed alternation in the rodent, a PFC-sensitive cognitive task, was ameliorated by systemic pretreatment with AMPA/kainate receptor antagonist LY293558. These findings suggest that ketamine may disrupt dopaminergic neurotransmission in the PFC as well as cognitive functions associated with this region, in part, by increasing the release of glutamate, thereby stimulating postsynaptic non-NMDA glutamate receptors.

Key words: microdialysis; phencyclidine; schizophrenia; working memory; antipsychotic drugs; AMPA receptors




This article has been cited by other articles:


Home page
J. Neurosci.Home page
K. Y. Tseng, B. L. Lewis, T. Hashimoto, S. R. Sesack, M. Kloc, D. A. Lewis, and P. O'Donnell
A Neonatal Ventral Hippocampal Lesion Causes Functional Deficits in Adult Prefrontal Cortical Interneurons
J. Neurosci., November 26, 2008; 28(48): 12691 - 12699.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
J. A. Lieberman, F. P. Bymaster, H. Y. Meltzer, A. Y. Deutch, G. E. Duncan, C. E. Marx, J. R. Aprille, D. S. Dwyer, X.-M. Li, S. P. Mahadik, et al.
Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection
Pharmacol. Rev., September 1, 2008; 60(3): 358 - 403.
[Abstract] [Full Text] [PDF]


Home page
J PsychopharmacolHome page
M. Schonenberg, U. Reichwald, G. Domes, A. Badke, and M. Hautzinger
Ketamine aggravates symptoms of acute stress disorder in a naturalistic sample of accident victims
J Psychopharmacol, July 1, 2008; 22(5): 493 - 497.
[Abstract] [PDF]


Home page
J. Neurosci.Home page
J. J. Chrobak, J. R. Hinman, and H. R. Sabolek
Revealing Past Memories: Proactive Interference and Ketamine-Induced Memory Deficits
J. Neurosci., April 23, 2008; 28(17): 4512 - 4520.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
H. Homayoun and B. Moghaddam
NMDA Receptor Hypofunction Produces Opposite Effects on Prefrontal Cortex Interneurons and Pyramidal Neurons
J. Neurosci., October 24, 2007; 27(43): 11496 - 11500.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
P.R. Corlett, G.K. Murray, G.D. Honey, M.R.F. Aitken, D.R. Shanks, T.W. Robbins, E.T. Bullmore, A. Dickinson, and P.C. Fletcher
Disrupted prediction-error signal in psychosis: evidence for an associative account of delusions
Brain, September 1, 2007; 130(9): 2387 - 2400.
[Abstract] [Full Text] [PDF]


Home page
J PsychopharmacolHome page
J. M. Stone, P. D. Morrison, and L. S. Pilowsky
Review: Glutamate and dopamine dysregulation in schizophrenia a synthesis and selective review
J Psychopharmacol, June 1, 2007; 21(4): 440 - 452.
[Abstract] [PDF]


Home page
J PsychopharmacolHome page
P.R. Corlett, G.D. Honey, and P.C. Fletcher
From prediction error to psychosis: ketamine as a pharmacological model of delusions
J Psychopharmacol, May 1, 2007; 21(3): 238 - 252.
[Abstract] [PDF]


Home page
J PsychopharmacolHome page
C. H. Large
Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs?
J Psychopharmacol, May 1, 2007; 21(3): 283 - 301.
[Abstract] [PDF]


Home page
J PsychopharmacolHome page
K. Heekeren, A. Neukirch, J. Daumann, M. Stoll, M. Obradovic, K.-A. Kovar, M.A. Geyer, and E. GouzouLis-Mayfrank
Prepulse inhibition of the startle reflex and its attentional modulation in the human S-ketamine and N,N-dimethyltryptamine (DMT) models of psychosis
J Psychopharmacol, May 1, 2007; 21(3): 312 - 320.
[Abstract] [PDF]


Home page
NeuroscientistHome page
C. R. Yang and L. Chen
Targeting Prefrontal Cortical Dopamine D1 and N-Methyl-D-Aspartate Receptor Interactions in Schizophrenia Treatment
Neuroscientist, October 1, 2005; 11(5): 452 - 470.
[Abstract] [PDF]


Home page
Arch Gen PsychiatryHome page
J. H. Krystal, E. B. Perry Jr, R. Gueorguieva, A. Belger, S. H. Madonick, A. Abi-Dargham, T. B. Cooper, L. MacDougall, W. Abi-Saab, and D. C. D'Souza
Comparative and Interactive Human Psychopharmacologic Effects of Ketamine and Amphetamine: Implications for Glutamatergic and Dopaminergic Model Psychoses and Cognitive Function
Arch Gen Psychiatry, September 1, 2005; 62(9): 985 - 994.
[Abstract] [Full Text] [PDF]


Home page
J PsychopharmacolHome page
O. P. Dall'igna, A. B.L. Tort, D. O. Souza, and D. R. Lara
Cinnarizine has an atypical antipsychotic profile in animal models of psychosis
J Psychopharmacol, July 1, 2005; 19(4): 342 - 346.
[Abstract] [PDF]


Home page
Cereb CortexHome page
G.D. Honey, R.A.E. Honey, C. O'Loughlin, S.R. Sharar, D. Kumaran, J. Suckling, D.K. Menon, C. Sleator, E.T. Bullmore, and P.C. Fletcher
Ketamine Disrupts Frontal and Hippocampal Contribution to Encoding and Retrieval of Episodic Memory: An fMRI Study
Cereb Cortex, June 1, 2005; 15(6): 749 - 759.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
V. Yarotskyy, A. V. Glushakov, C. Sumners, N. Gravenstein, D. M. Dennis, C. N. Seubert, and A. E. Martynyuk
Differential Modulation of Glutamatergic Transmission by 3,5-Dibromo-L-phenylalanine
Mol. Pharmacol., May 1, 2005; 67(5): 1648 - 1654.
[Abstract] [Full Text] [PDF]


Home page
J. Neurophysiol.Home page
H. Homayoun, M. E. Jackson, and B. Moghaddam
Activation of Metabotropic Glutamate 2/3 Receptors Reverses the Effects of NMDA Receptor Hypofunction on Prefrontal Cortex Unit Activity in Awake Rats
J Neurophysiol, April 1, 2005; 93(4): 1989 - 2001.
[Abstract] [Full Text] [PDF]


Home page
Am. J. PsychiatryHome page
L. M. Rowland, J. R. Bustillo, P. G. Mullins, R. E. Jung, R. Lenroot, E. Landgraf, R. Barrow, R. Yeo, J. Lauriello, and W. M. Brooks
Effects of Ketamine on Anterior Cingulate Glutamate Metabolism in Healthy Humans: A 4-T Proton MRS Study
Am J Psychiatry, February 1, 2005; 162(2): 394 - 396.
[Abstract] [Full Text] [PDF]


Home page
Am. J. PsychiatryHome page
I. L. Petrakis, D. Limoncelli, R. Gueorguieva, P. Jatlow, N. N. Boutros, L. Trevisan, J. Gelernter, and J. H. Krystal
Altered NMDA Glutamate Receptor Antagonist Response in Individuals With a Family Vulnerability to Alcoholism
Am J Psychiatry, October 1, 2004; 161(10): 1776 - 1782.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
M. E. Jackson, H. Homayoun, and B. Moghaddam
NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex
PNAS, June 1, 2004; 101(22): 8467 - 8472.
[Abstract] [Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
V Di Lazzaro, A Oliviero, F Pilato, E Saturno, M Dileone, C Marra, A Daniele, S Ghirlanda, G Gainotti, and P A Tonali
Motor cortex hyperexcitability to transcranial magnetic stimulation in Alzheimer's disease
J. Neurol. Neurosurg. Psychiatry, April 1, 2004; 75(4): 555 - 559.
[Abstract] [Full Text] [PDF]


Home page
Physiol. GenomicsHome page
S. Kaiser and L. K. Nisenbaum
Evaluation of common gene expression patterns in the rat nervous system
Physiol Genomics, December 16, 2003; 16(1): 1 - 7.
[Abstract] [Full Text] [PDF]


Home page
Cereb CortexHome page
J. K. Seamans, L. Nogueira, and A. Lavin
Synaptic Basis of Persistent Activity in Prefrontal Cortex In Vivo and in Organotypic Cultures
Cereb Cortex, November 1, 2003; 13(11): 1242 - 1250.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
G. E. Duncan, S. Miyamoto, and J. A. Lieberman
Chronic Administration of Haloperidol and Olanzapine Attenuates Ketamine-Induced Brain Metabolic Activation
J. Pharmacol. Exp. Ther., June 1, 2003; 305(3): 999 - 1005.
[Abstract] [Full Text] [PDF]


Home page
Arch Gen PsychiatryHome page
K. L. Davis, D. G. Stewart, J. I. Friedman, M. Buchsbaum, P. D. Harvey, P. R. Hof, J. Buxbaum, and V. Haroutunian
White Matter Changes in Schizophrenia: Evidence for Myelin-Related Dysfunction
Arch Gen Psychiatry, May 1, 2003; 60(5): 443 - 456.
[Abstract] [Full Text] [PDF]


Home page
Mol. Interv.Home page
S. Miyamoto, A. S. LaMantia, G. E. Duncan, P. Sullivan, J. H. Gilmore, and J. A. Lieberman
Recent Advances in the Neurobiology of Schizophrenia
Mol. Interv., February 1, 2003; 3(1): 27 - 39.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
C. Wang, J. McInnis, J. B. West, J. Bao, N. Anastasio, J. A. Guidry, Y. Ye, D. Salvemini, and K. M. Johnson
Blockade of Phencyclidine-Induced Cortical Apoptosis and Deficits in Prepulse Inhibition by M40403, a Superoxide Dismutase Mimetic
J. Pharmacol. Exp. Ther., January 1, 2003; 304(1): 266 - 271.
[Abstract] [Full Text] [PDF]


Home page
Br J AnaesthHome page
D. Ma, S. Wilhelm, M. Maze, and N. P. Franks
Neuroprotective and neurotoxic properties of the 'inert' gas, xenon
Br. J. Anaesth., November 1, 2002; 89(5): 739 - 746.
[Abstract] [Full Text] [PDF]


Home page
Am. J. PsychiatryHome page
M. R. Gluck, R. G. Thomas, K. L. Davis, and V. Haroutunian
Implications for Altered Glutamate and GABA Metabolism in the Dorsolateral Prefrontal Cortex of Aged Schizophrenic Patients
Am J Psychiatry, July 1, 2002; 159(7): 1165 - 1173.
[Abstract] [Full Text] [PDF]


Home page
Arch Gen PsychiatryHome page
J. H. Krystal, A. Anand, and B. Moghaddam
Effects of NMDA Receptor Antagonists: Implications for the Pathophysiology of Schizophrenia
Arch Gen Psychiatry, July 1, 2002; 59(7): 663 - 664.
[Full Text] [PDF]


Home page
Adv. Psychiatr. Treat.Home page
E. M. Tsapakis and M. J. Travis
Glutamate and psychiatric disorders
Advan. Psychiatr. Treat., May 1, 2002; 8(3): 189 - 197.
[Full Text] [PDF]


Home page
Am. J. PsychiatryHome page
D. C. Goff and J. T. Coyle
The Emerging Role of Glutamate in the Pathophysiology and Treatment of Schizophrenia
Am J Psychiatry, September 1, 2001; 158(9): 1367 - 1377.
[Abstract] [Full Text] [PDF]


Home page
Cereb CortexHome page
J. Wang and P. O'Donnell
D1 Dopamine Receptors Potentiate NMDA-mediated Excitability Increase in Layer V Prefrontal Cortical Pyramidal Neurons
Cereb Cortex, May 1, 2001; 11(5): 452 - 462.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
Y. Miyamoto, K. Yamada, Y. Noda, H. Mori, M. Mishina, and T. Nabeshima
Hyperfunction of Dopaminergic and Serotonergic Neuronal Systems in Mice Lacking the NMDA Receptor {epsilon}1 Subunit
J. Neurosci., January 15, 2001; 21(2): 750 - 757.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
E. K. Lambe, L. S. Krimer, and P. S. Goldman-Rakic
Differential Postnatal Development of Catecholamine and Serotonin Inputs to Identified Neurons in Prefrontal Cortex of Rhesus Monkey
J. Neurosci., December 1, 2000; 20(23): 8780 - 8787.
[Abstract] [Full Text] [PDF]


Home page
Arch Gen PsychiatryHome page
D. Umbricht, L. Schmid, R. Koller, F. X. Vollenweider, D. Hell, and D. C. Javitt
Ketamine-Induced Deficits in Auditory and Visual Context-Dependent Processing in Healthy Volunteers: Implications for Models of Cognitive Deficits in Schizophrenia
Arch Gen Psychiatry, December 1, 2000; 57(12): 1139 - 1147.
[Abstract] [Full Text] [PDF]


Home page
Arch Gen PsychiatryHome page
D. C. Javitt, U. Heresco-Levy, N. B. Farber, J. W. Newcomer, and J. W. Olney
Are Glycine Sites Saturated In Vivo?
Arch Gen Psychiatry, December 1, 2000; 57(12): 1181 - 1183.
[Full Text] [PDF]


Home page
Arch Gen PsychiatryHome page
A. Anand, D. S. Charney, D. A. Oren, R. M. Berman, X. S. Hu, A. Cappiello, and J. H. Krystal
Attenuation of the Neuropsychiatric Effects of Ketamine With Lamotrigine: Support for Hyperglutamatergic Effects of N-methyl-D-aspartate Receptor Antagonists
Arch Gen Psychiatry, March 1, 2000; 57(3): 270 - 276.
[Abstract] [Full Text] [PDF]


Home page
Arch NeurolHome page
J. C. M. Brust
Substance Abuse, Neurobiology, and Ideology
Arch Neurol, December 1, 1999; 56(12): 1528 - 1531.
[Full Text] [PDF]


Home page
J. Neurosci.Home page
S. Otani, N. Auclair, J.-M. Desce, M.-P. Roisin, and F. Crepel
Dopamine Receptors and Groups I and II mGluRs Cooperate for Long-Term Depression Induction in Rat Prefrontal Cortex through Converging Postsynaptic Activation of MAP Kinases
J. Neurosci., November 15, 1999; 19(22): 9788 - 9802.
[Abstract] [Full Text] [PDF]


Home page
Arch Gen PsychiatryHome page
N. B. Farber, J. W. Newcomer, and J. W. Olney
Glycine Agonists: What Can They Teach Us About Schizophrenia?
Arch Gen Psychiatry, January 1, 1999; 56(1): 13 - 17.
[Full Text] [PDF]


Home page
J. Neurosci.Home page
V. P. Bakshi and M. A. Geyer
Multiple Limbic Regions Mediate the Disruption of Prepulse Inhibition Produced in Rats by the Noncompetitive NMDA Antagonist Dizocilpine
J. Neurosci., October 15, 1998; 18(20): 8394 - 8401.
[Abstract] [Full Text] [PDF]


Home page
ScienceHome page
B. Moghaddam and B. W. Adams
Reversal of Phencyclidine Effects by a Group II Metabotropic Glutamate Receptor Agonist in Rats
Science, August 28, 1998; 281(5381): 1349 - 1352.
[Abstract] [Full Text]


Home page
J. Neurosci.Home page
B. Adams and B. Moghaddam
Corticolimbic Dopamine Neurotransmission Is Temporally Dissociated from the Cognitive and Locomotor Effects of Phencyclidine
J. Neurosci., July 15, 1998; 18(14): 5545 - 5554.
[Abstract] [Full Text] [PDF]



-

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help

-
Copyright 2009 by Society for Neuroscience ONLINE ISSN: 1529-2401
-